# Castle Biosciences, Inc. (CSTL)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $611M  
**Price:** $21.08

> Castle Biosciences, Inc. is a molecular diagnostics company that develops and provides innovative gene expression profile tests to guide patient care in oncology and related fields. Its portfolio includes DecisionDx-Melanoma, a risk stratification test predicting metastasis risk in cutaneous melanoma patients; DecisionDx-SCC for assessing recurrence and metastasis risk in cutaneous squamous cell carcinoma; DecisionDx-UM for uveal melanoma metastasis risk; MyPath Melanoma, a diagnostic tool for challenging melanoma cases; and TissueCypher for evaluating progression risk in Barrett’s esophagus patients. These tests support clinical decisions in dermatologic cancers, esophageal conditions, and uveal melanoma by offering personalized risk assessments that inform treatment pathways. Castle Biosciences, Inc. focuses on areas where precise diagnostics can improve outcomes, such as identifying low-risk patients to avoid overtreatment and high-risk individuals for intensified monitoring. Founded in 2008 and headquartered in Friendswood, Texas, the company operates at the intersection of precision medicine and healthcare, delivering tests that enhance decision-making for physicians and patients across these specialized medical domains.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $344M | $273M | -$43M | -$24M | — |
| 2024 | $332M | $272M | $9M | $18M | — |
| 2023 | $220M | $175M | -$68M | -$57M | — |
| 2022 | $137M | $105M | -$73M | -$67M | — |
| 2021 | $94M | $78M | -$40M | -$31M | — |
| 2020 | $63M | $53M | -$7M | -$10M | — |
| 2019 | $52M | $45M | $7M | $5M | — |
| 2018 | $23M | $17M | -$4M | -$6M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $579M | $108M | $471M | $117M | $10M |
| 2024 | $531M | $75M | $456M | $120M | $10M |
| 2023 | $453M | $62M | $391M | $99M | — |
| 2022 | $447M | $48M | $399M | $123M | — |
| 2021 | $463M | $51M | $412M | $330M | — |
| 2020 | $439M | $24M | $416M | $410M | — |
| 2019 | $120M | $35M | $85M | $99M | $27M |
| 2018 | $22M | $32M | -$57M | $4M | $25M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $64M | $36M | $28M |
| 2024 | $65M | $28M | $37M |
| 2023 | -$6M | $14M | -$19M |
| 2022 | -$42M | $6M | -$47M |
| 2021 | -$19M | $3M | -$22M |
| 2020 | $10M | $5M | $5M |
| 2019 | $7M | $937,000 | $6M |
| 2018 | -$12M | $277,000 | -$13M |

Source: [CompaniesByCap](https://companiesbycap.com/company/CSTL)